Liquidia Corporation
IPOJust breathe
- Headquarters
- Morrisville, North Carolina
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- liquidia.com
- Last Round
- Venture RoundJun 2025
- Rounds
- 6
- Type
- Public
About
Liquidia Corporation is a publicly traded biopharmaceutical company focused on developing and commercializing innovative therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). The company leverages its proprietary PRINT nanotechnology platform to engineer inhaled therapies with enhanced efficacy and tolerability. Liquidia trades on Nasdaq as LQDA and is headquartered in Morrisville, North Carolina.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jun 2025
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biopharmaceutical company developing sustained-release hydrogel therapies targeting retinal disea...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...